Emerging Markets GSK-Novartis Battleground For Lung-Disease Drugs
This article was originally published in PharmAsia News
Executive Summary
The world's emerging markets are becoming a battleground for GlaxoSmithKline and Novartis as they battle for control of a $10 billion global market for treating lung diseases caused primarily by smoking.